Back to top

RegenXBio (RGNX) was downgraded to a Hold Rating at Barclays

In a report released today, Eliana Merle from Barclays downgraded RegenXBio to a Hold, with a price target of $12.00. Merle covers the Healthcare s...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

REGENXBIO Inc. (RGNX)